Can artificial intelligence break the rare disease deadlock?

11:00 AM - 12:00 PM, Wednesday, June 10, 2020 ・ Room 5A
Delivering effective treatments for patients suffering from rare diseases is a major global health challenge. Over 7000 rare diseases affect 300 million globally. Less than 10% of patients receive treatment, and only 1% are managed using an approved protocol. Delayed diagnosis and lack of quality information are common denominators in the odyssey faced by patients. Diagnoses can often reach a dead end, with no concrete medical or clinical treatment options. Could artificial intelligence (AI) break this vicious circle? Would an AI algorithm, fed by high quality data, and employing sophisticated pattern recognition, hold the key to better diagnosis pathways? AI could facilitate screening of patients at risk and subsequent referrals, and enable early interventions to prevent degenerative progression of the disease. This breakthrough could fuel the development of new therapies for rare disorders and deliver better care.
Moderator
photo
Executive Director
Innovative Medicines Initiative (IMI)
Speakers
photo
Head of the Bioinformatics Unit
Spanigh National Centre of Genomic Analysis
photo
President and CEO
The Ehlers-Danlos Society
photo
Chairman and Founder
RDMD
photo
Director, Data Science
Pfizer
photo
President and CEO
Rady Children's Institute for Genomic Medicine